Raising high-density lipoprotein cholesterol: Innovative strategies against an old adversary

Current Atherosclerosis Reports

Volumn 7, Issue 2, 2005, Pages 88-94

  Kazi, Dhruv ^a   Farmer, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; APOLIPOPROTEIN A1; ATORVASTATIN; BILE ACID SEQUESTRANT; CHLORIDE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; ETC 216; FIBRIC ACID DERIVATIVE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID DERIVATIVE; PLACEBO; TORCETRAPIB; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; BLOATING; CHOLELITHIASIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONSTIPATION; CORONARY RISK; DIVERTICULITIS; DRUG ERUPTION; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; EXCRETION; FLATULENCE; FLUSHING; GASTROINTESTINAL DISEASE; GENE MUTATION; HETEROZYGOSITY; HUMAN; HYPERCHLOREMIC ACIDOSIS; HYPERTRIGLYCERIDEMIA; HYPOTHESIS; INSOMNIA; LIVER DYSFUNCTION; LIVER FUNCTION; META ANALYSIS; MYOPATHY; NAUSEA; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW;

EID: 17044439806     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-005-0029-x     Document Type: Review

References (52)

1. Fanceschini G: Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol 2001, 88:9N-13N.
2. Gordon DJ, Probstfield JL, Garrison RJ, et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
3. Gotto AM Jr, Brinton EA: Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004, 43:717-724.
4. Wang M, Briggs MR: HDL: the metabolism, function, and therapeutic importance. Chem Rev 2004, 104:119-137.
5. Genest J Jr, Marcil M, Denis M, Yu L: High density lipoproteins in health and in disease. J Invest Med 1999, 47: 1-42.
6. Nofer JR, Kehrel B, Fobker M, et al.: HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 2002, 161:1-16.
7. Navab M, Imes SS, Hama SY, et al.: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991, 88:2039-2046.
8. Nofer JR, Walter M, Kehrel B, et al.: HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998, 18:861-869.
9. Fleisher LN, Tall AR, Witte LD, et al.: Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem 1982, 257:6653-6655.
10. Yuhanna IS, Zhu Y, Cox BE, et al.: High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001, 7:853-857.
11. Drew BG, Fidge NH, Gallon-Beaumier G, et al.: High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci U S A 2004, 101:6999-7004.
12. Castle CK, Pape ME, Marotti KR, Melchior GW: Secretion of pre-beta-migrating apoA-I by cynomolgus monkey hepatocytes in culture. J Lipid Res 1991, 32:439-447.
13. Musliner TA, Long MD, Forte TM, et al.: Dissociation of high density lipoprotein precursors from apolipoprotein B-containing lipoproteins in the presence of unesterified fatty acids and a source of apolipoprotein A-I. J Lipid Res 1991, 32:917-933.
14. Patsch JR, Gotto AM Jr, Olivercrona T, Eisenberg S: Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro. Proc Natl Acad Sci U S A 1978, 75:4519-4523.
15. Dieplinger H, Zechner R, Kostner GM: The in vitro formation of HDL2 during the action of LCAT: the role of triglyceride-rich lipoproteins. J Lipid Res 1985, 26: 73-282.
16. Rye KA, Clay MA, Barter PJ: Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999, 145: 27-238.
17. Ji,Y, Jian B, Wang N, et al.: Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997, 272:20982-20985.
18. Lusa S, Jauhiainen M, Metso J, et al.: The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J 1996, 313 (Pt 1):275-282.
19. Acton S, Rigotti A, Landschulz KT, et al.: Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996, 271:518-520.
20. Silver DL, Wang N, Xiao X, Tall AR: High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J Biol Chem 2001, 276: 5287-25293.
21. Kozyraki R: Cubilin, a multifunctional epithelial receptor: an overview. J Mol Med 2000, 79:161-167.
22. Tall AR: Plasma cholesteryl ester transfer protein. J Lipid Res 1993, 34:1255-1274.
23. Goldberg DI, Beltz WF, Pittman RC: Evaluation of pathways for the cellular uptake of high density lipoprotein cholesterol esters in rabbits. J Clin Invest 1991, 87:331-346.
24. Genest JJ, McNamara JR, Salem DN, et al.: Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991, 67:1185-1189.
25. Castelli WP: Cholesterol and lipids in the risk of coronary artery disease - the Framingham Heart Study. Can J Cardiol 1988, 4(Suppl A):5A-10A.
26. Assmann G, Schulte H: Role of triglycerides in coronary artery disease: lessons from the Prospective Cardiovascular Munster Study. Am J Cardiol 1992, 70:10H-13H.
27. Glueck CJ, Fallat RW, Millett F, et al.: Familial hyper-alpha-lipoproteinemia: studies in eighteen kindreds. Metabolism 1975, 24:1243-1265.
28. Franceschini G, Sirtori CR, Capurso A, et al.: A-I Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980, 66: 92-900.
29. Weisgraber KH, Rall SC Jr, Bersot TP, et al.: Apolipoprotein A-I Milano. Detection of normal A-I in affected subjects and evidence for a cysteine for arginine substitution in the variant A-I. J Biol Chem 1983, 258:2508-2513.
30. Franceschini G, Sirtori CR, Bosisio E, et al.: Relationship of the phenotypic expression of the A-I Milano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis 1985, 58:159-174.
31. Gualandri V, Franceschini G, Sirtori CR, et al.: A-I Milano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985, 37: 083-1097.
32. Franceschini G, Calabresi L, Chiesa G, et al.: Increased cholesterol efflux potential of sera from ApoA-I Milano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 1999, 19:1257-1262.
33. Bielicki JK, Oda MN: Apolipoprotein A-I (Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 2002, 41: 089-2096.
34. Shah PK, Yano J, Reyes O, et al.: High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001, 103:3047-3050.
35. Chiesa G, Monteggia E, Marchesi M, et al.: Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002, 90:974-980.
36. Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290:2292-2300.
37. Kaul S, Rukshin V, Santos R, et al.: Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003, 107:2551-2554.
38. Koizumi J, Mabuchi H, Yoshimura A, et al.: Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia. Atherosclerosis 1985, 58:175-186.
39. Brown ML, Inazu H, Hesler CB, et al.: Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989, 342:448-451.
40. Inazu A, Brown ML, Hesler CB, et al.: Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990, 323: 234-1238.
41. Sugano M, Makino N, Sawada S, et al.: Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998, 273:5033-5036.
42. Whitlock ME, Swenson TL, Ramakrishnan R, et al.: Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J Clin Invest 1989, 84:129-137.
43. Gaynor BJ, Sand T, Clark RW, et al.: Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition. Atherosclerosis 1994, 110:101-109.
44. Rittershaus CW, Miller DP, Thomas LJ, et al.: Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000, 20:2106-2112.
45. Kothari HV, Poirier KJ, Lee WH, Satoh Y: Inhibition of cholesterol ester transfer protein CGS 25159 and changes in lipoproteins in hamsters. Atherosclerosis 1997, 128:59-66.
46. Okamoto H, Yonemori F, Wakitani K, et al.: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406:203-207.
47. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al.: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002, 105:2159-2165.
48. Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505-1515.
49. Lamarche B, Tchernof A, Moorjani S, et al.: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95:69-75.
50. Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al.: Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition) - Norfolk population study. Circulation 2004, 110: 418-1423.
51. Barter PJ, Brewer HB, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160-167.
52. Reddy KS: Cardiovascular disease in non-Western countries. N Engl J Med 2004, 350:2438-2440.